Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib plus mFOLFOX6 as first-line therapy for metastatic colorectal adenocarcinoma
2010-020121-41Phase 2Completed
- Sponsor
- Bayer
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of regorafenib in colorectal adenocarcinoma (mCRC), sponsored by Bayer. Primary endpoint: Objective tumor response rate. Started Nov 2010; status: completed.
02
Drugs
regorafenib
03
Conditions
colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2010-020121-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020121-41.